title: Points to Consider in Designing Mesenchymal Stem Cell-Based Clinical Trials.
abstract: SUMMARY: Therapeutic applications of cells are likely to increase greatly in the future. Cell and cell-based gene therapy manufacturing facilities need to be purpose-designed and accredited by their national medicinal regulatory body. Production scientists need to work in close tandem with quality assurance and ethics committees to absolutely ensure the safety of new cellular products. In this review, we consider the need for preclinical safety and efficacy data, tissue source for manufacture of clinical grade human mesenchymal stem cells, aseptic tissue processing, indemnification, and the role of the national medicinal regulatory body in appropriate clinical trial design.
authors.affiliation: Mater Medical Research Institute, Brisbane, Queensland, Australia.
authors.forename: Gary
authors.initials: G
authors.lastname: Brooke
authors.forename: Tony
authors.initials: T
authors.lastname: Rossetti
authors.forename: Nina
authors.initials: N
authors.lastname: Ilic
authors.forename: Patricia
authors.initials: P
authors.lastname: Murray
authors.forename: Sonia
authors.initials: S
authors.lastname: Hancock
authors.forename: Rebecca
authors.initials: R
authors.lastname: Pelekanos
authors.forename: Kerry
authors.initials: K
authors.lastname: Atkinson